🔎 Trials Near Me

Home › Pulmonary Embolism › NCT06433011

The RAPID - PE Study: RESCUE Advanced Protocol for the Treatment of Pulmonary Embolism

Recruiting

The RAPID - PE Study: RESCUE Advanced Protocol Without ICU Stay and no Lytic Drip - for the Treatment of Pulmonary Embolism

Who can join

All ages · All sexes

Full eligibility criteria
Inclusion Criteria

1. Willing and able to provide informed consent;
2. PE symptom duration ≤ 15 days;
3. Filling defect in at least one major lobar pulmonary artery as determined by CTA;
4. Patient is diagnosed with intermediate risk PE;
5. RV/LV diameter ratio ≥ 0.9 by CTA, as determined by investigative site;
6. Willing and able to comply with all study procedures and 7-day and 30-day telephone follow-up visit.

Exclusion Criteria:

1. Previous history of stroke with residual hemiplegia;
2. Major surgery ≤ 10 days prior to inclusion in the study;
3. Platelet count \< 100,000/μL;
4. Pulmonary thrombectomy within the previous 4 days;
5. Uncontrolled hypertension defined as systolic blood pressure \>180 mm Hg and/or diastolic blood pressure \>110 mm Hg at the time of the procedure;
6. Administration of thrombolytic agents within the previous 4 days;
7. Absolute contraindication to anticoagulation;
8. Clinician deems high-risk for catastrophic bleeding;
9. Pregnancy;
10. Any vasopressor or inotropic support;
11. Cardiac arrest (including pulseless electrical activity (PEA) and asystole) requiring active cardiopulmonary resuscitation (CPR) during this hospitalization at treating institution and/or referring institution;
12. Planning to administer r-tPA by infusion after the r-tPA is administered by pulse sprays;
13. Currently participating in another study;
14. In the opinion of the investigator, the subject is not a suitable candidate for the study.

About the study

To demonstrate the efficacy and safety of the 8F BASHIR™ .035 Endovascular Catheter and the 8F BASHIR™ S-B .035 Endovascular Catheter for the administration of pharmaco-mechanical catheter directed therapy using pulse sprays of r-tPA into the pulmonary arteries for the treatment of intermediate risk pulmonary embolism (PE).

What is being tested

Sponsor: Thrombolex, Inc. · Participants: 500 · Started: Oct 17, 2024

Contact the study team

Official record on ClinicalTrials.gov — NCT06433011

Locations in the U.S.

ArizonaHonor Health, Scottsdale
Carondelet St. Joseph's Hospital, Tuscon
FloridaRadiology and Imaging Specialists, Lakeland
GeorgiaEmory University, Atlanta
IllinoisRush University Medical Center, Chicago
IndianaProfound Research, Hobart
Community Health, Indianapolis
MassachusettsBeth Israel Deaconess Medical Center, Boston
Boston Medical Center, Boston
Lahey Hospital & Medical Center, Burlington
MississippiNorth Mississippi Medical Center, Tupelo
New HampshireDartmouth Hitchcock, Lebanon
New JerseyCooper Health, Camden
New YorkSt. Joseph's, Liverpool
Northwell Health, Manhasset
Mount Sinai, New York
OhioTriHealth, Cincinnati
Miami Valley/Wright State University/Premier Health, Dayton
Jobst Vascular Institute - ProMedica Hospital, Toledo
PennsylvaniaTemple University, Philadelphia
TennesseeVanderbilt University Medical Center, Nashville
VirginiaSentara, Norfolk
West VirginiaCharleston Area Medical Center, Charleston

Conditions

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.